Calcitriol attenuates cardiac remodeling and dysfunction in a murine model of polycystic ovary syndrome

Endocrine

Volumn 52, Issue 2, 2016, Pages 363-373

  Gao, Ling ^a   Cao, Jia Tian ^a   Liang, Yan ^a   Zhao, Yi Chao ^a   Lin, Xian Hua ^a   Li, Xiao Cui ^a   Tan, Ya Jing ^a   Li, Jing Yi ^a,b   Zhou, Cheng Liang ^b   Xu, Hai Yan ^b   Sheng, Jian Zhong ^b,c   Huang, He Feng ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Calcitriol; Cardiac remodeling; Polycystic ovary syndrome; Vitamin D

Indexed keywords

ANDROSTANOLONE; CALCITRIOL; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CONNECTIVE TISSUE GROWTH FACTOR; FIBRONECTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; VITAMIN D; CALCIUM CHANNEL STIMULATING AGENT; MTOR PROTEIN, MOUSE; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOPHAGY; C57BL 6 MOUSE; CARDIAC REMODELING; CELL SURVIVAL; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; DYSLIPIDEMIA; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ESTRUS CYCLE; FEMALE; FIBROSING ALVEOLITIS; HEART DISEASE; HEART FUNCTION; HEART MUSCLE CELL; HEART REMODELING; HEART STRUCTURE; HEART VENTRICLE HYPERTROPHY; HOMEOSTASIS; INFANT; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; OBESITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; VITAMIN SUPPLEMENTATION; ANIMAL; C57BL MOUSE; CARDIAC MUSCLE; CARDIAC MUSCLE CELL; DISEASE MODEL; DRUG EFFECTS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; POLYCYSTIC OVARY SYNDROME; RANDOMIZATION;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; AUTOPHAGY; CALCITRIOL; CALCIUM CHANNEL AGONISTS; DISEASE MODELS, ANIMAL; FEMALE; MICE, INBRED C57BL; MYOCARDIUM; MYOCYTES, CARDIAC; PHOSPHORYLATION; POLYCYSTIC OVARY SYNDROME; RANDOM ALLOCATION; TOR SERINE-THREONINE KINASES;

EID: 84947420816     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-015-0797-1     Document Type: Article

References (46)

1. M.O. Goodarzi, D.A. Dumesic, G. Chazenbalk, R. Azziz, Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat. Rev. Endocrinol. 7(4), 219–231 (2011). doi:10.1038/nrendo.2010.217
2. C.N. Jayasena, S. Franks, The management of patients with polycystic ovary syndrome. Nat. Rev. Endocrinol. 10(10), 624–636 (2014). doi:10.1038/nrendo.2014.102
3. H.S. Randeva, B.K. Tan, M.O. Weickert, K. Lois, J.E. Nestler, N. Sattar, H. Lehnert, Cardiometabolic aspects of the polycystic ovary syndrome. Endocr. Rev. 33(5), 812–841 (2012). doi:10.1210/er.2012-1003
4. H. Mani, M.J. Levy, M.J. Davies, D.H. Morris, L.J. Gray, J. Bankart, H. Blackledge, K. Khunti, T.A. Howlett, Diabetes and cardiovascular events in women with polycystic ovary syndrome: a 20-year retrospective cohort study. Clin. Endocrinol. 78(6), 926–934 (2013). doi:10.1111/cen.12068
5. P.C. de Groot, O.M. Dekkers, J.A. Romijn, S.W. Dieben, F.M. Helmerhorst, PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis. Hum. Reprod. Update 17(4), 495–500 (2011). doi:10.1093/humupd/dmr001
6. T. Oka, H. Akazawa, A.T. Naito, I. Komuro, Angiogenesis and cardiac hypertrophy: maintenance of cardiac function and causative roles in heart failure. Circ. Res. 114(3), 565–571 (2014). doi:10.1161/circresaha.114.300507
7. K. Lakhani, N. Constantinovici, W.M. Purcell, R. Fernando, P. Hardiman, Internal carotid artery haemodynamics in women with polycystic ovaries. Clin. Sci. (Lond.) 98(6), 661–665 (2000)
8. G. Masszi, E.M. Horvath, R. Tarszabo, R. Benko, A. Novak, A. Buday, A.M. Tokes, G.L. Nadasy, P. Hamar, Z. Benyo, S. Varbiro, Reduced estradiol-induced vasodilation and poly-(ADP-ribose) polymerase (PARP) activity in the aortas of rats with experimental polycystic ovary syndrome (PCOS). PLoS One 8(3), e55589 (2013). doi:10.1371/journal.pone.0055589
9. S. Varbiro, L. Sara, P. Antal, A. Monori-Kiss, A.M. Tokes, E. Monos, R. Benko, N. Csibi, M. Szekeres, R. Tarszabo, A. Novak, P. Paragi, G.L. Nadasy, Lower-limb veins are thicker and vascular reactivity is decreased in a rat PCOS model: concomitant vitamin D3 treatment partially prevents these changes. Am. J. Physiol. Heart Circ. Physiol. 307(6), H848–H857 (2014). doi:10.1152/ajpheart.01024.2013
10. R. Calderon-Margalit, D. Siscovick, S.S. Merkin, E. Wang, M.L. Daviglus, P.J. Schreiner, B. Sternfeld, O.D. Williams, C.E. Lewis, R. Azziz, S.M. Schwartz, M.F. Wellons, Prospective association of polycystic ovary syndrome with coronary artery calcification and carotid-intima-media thickness: the Coronary Artery Risk Development in Young Adults Women’s study. Arterioscler. Thromb. Vasc. Biol. 34(12), 2688–2694 (2014). doi:10.1161/atvbaha.114.304136
11. E.O. Talbott, D.S. Guzick, K. Sutton-Tyrrell, K.P. McHugh-Pemu, J.V. Zborowski, K.E. Remsberg, L.H. Kuller, Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler. Thromb. Vasc. Biol. 20(11), 2414–2421 (2000)
12. S. Tepavcevic, D.V. Milutinovic, D. Macut, M. Stojiljkovic, M. Nikolic, I. Bozic-Antic, T. Culafic, J. Bjekic-Macut, G. Matic, G. Koricanac, Cardiac fatty acid uptake and metabolism in the rat model of polycystic ovary syndrome. Endocrine (2015). doi:10.1007/s12020-015-0558-1
13. S. Tepavčević, D.V. Milutinović, D. Macut, Z. Žakula, M. Nikolić, I. Božić-Antić, S. Romic, J. Bjekic-Macut, G. Matic, G. Korićanac, Dihydrotestosterone deteriorates cardiac insulin signaling and glucose transport in the rat model of polycystic ovary syndrome. J. Steroid Biochem. Mol. Biol. 141, 71–76 (2014). doi:10.1016/j.jsbmb.2014.01.006
14. D. Levy, R.J. Garrison, D.D. Savage, W.B. Kannel, W.P. Castelli, Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N. Engl. J. Med. 322(22), 1561–1566 (1990). doi:10.1056/nejm199005313222203
15. N. Raja-Khan, J. Shah, C.M. Stetter, M.E. Lott, A.R. Kunselman, W.C. Dodson, R.S. Legro, High-dose vitamin D supplementation and measures of insulin sensitivity in polycystic ovary syndrome: a randomized, controlled pilot trial. Fertil. Steril. 101(6), 1740–1746 (2014). doi:10.1016/j.fertnstert.2014.02.021
16. H. Selimoglu, C. Duran, S. Kiyici, C. Ersoy, M. Guclu, G. Ozkaya, E. Tuncel, E. Erturk, S. Imamoglu, The effect of vitamin D replacement therapy on insulin resistance and androgen levels in women with polycystic ovary syndrome. J. Endocrinol. Invest. 33(4), 234–238 (2010). doi:10.3275/6560
17. T. Yao, X. Ying, Y. Zhao, A. Yuan, Q. He, H. Tong, S. Ding, J. Liu, X. Peng, E. Gao, J. Pu, B. He, Vitamin D receptor activation protects against myocardial reperfusion injury through inhibition of apoptosis and modulation of autophagy. Antioxid. Redox Signal. 22(8), 633–650 (2015). doi:10.1089/ars.2014.5887
18. M. Freundlich, Y.C. Li, Y. Quiroz, Y. Bravo, W. Seeherunvong, C. Faul, J.R. Weisinger, B. Rodriguez-Iturbe, Paricalcitol downregulates myocardial renin-angiotensin and fibroblast growth factor expression and attenuates cardiac hypertrophy in uremic rats. Am. J. Hypertens. 27(5), 720–726 (2014). doi:10.1093/ajh/hpt177
19. L.M. Meems, M.V. Cannon, H. Mahmud, A.A. Voors, W.H. van Gilst, H.H. Sillje, W.P. Ruifrok, R.A. de Boer, The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload. J. Steroid Biochem. Mol. Biol. 132(3–5), 282–289 (2012). doi:10.1016/j.jsbmb.2012.06.004
20. B.P. Rafacho, P. Santos, H.B. Assalin, L.P. Ardisson, M.G. Roscani, B.F. Polegato, F. Chiuso-Minicucci, A.A. Fernandes, P.S. Azevedo, M.F. Minicucci, L.A. Zornoff, S. Paiva, Role of vitamin D in the cardiac remodeling induced by tobacco smoke exposure. Int. J. Cardiol. 155(3), 472–473 (2012). doi:10.1016/j.ijcard.2011.12.078
21. A.S. Caldwell, L.J. Middleton, M. Jimenez, R. Desai, A.C. McMahon, C.M. Allan, D.J. Handelsman, K.A. Walters, Characterization of reproductive, metabolic, and endocrine features of polycystic ovary syndrome in female hyperandrogenic mouse models. Endocrinology 155(8), 3146–3159 (2014). doi:10.1210/en.2014-1196
22. E.L. van Houten, P. Kramer, A. McLuskey, B. Karels, A.P. Themmen, J.A. Visser, Reproductive and metabolic phenotype of a mouse model of PCOS. Endocrinology 153(6), 2861–2869 (2012). doi:10.1210/en.2011-1754
23. G. Masszi, A. Novak, R. Tarszabo, E.M. Horvath, A. Buday, E. Ruisanchez, A.M. Tokes, L. Sara, R. Benko, G.L. Nadasy, C. Revesz, P. Hamar, Z. Benyo, S. Varbiro, Effects of vitamin D3 derivative–calcitriol on pharmacological reactivity of aortic rings in a rodent PCOS model. Pharmacol. Rep. 65(2), 476–483 (2013)
24. Q. He, J. Pu, A. Yuan, W.B. Lau, E. Gao, W.J. Koch, X.L. Ma, B. He, Activation of liver-X-receptor alpha but not liver-X-receptor beta protects against myocardial ischemia/reperfusion injury. Circ. Heart Fail. 7(6), 1032–1041 (2014). doi:10.1161/circheartfailure.114.001260
25. P. Shan, J. Pu, A. Yuan, L. Shen, L. Shen, D. Chai, B. He, RXR agonists inhibit oxidative stress-induced apoptosis in H9c2 rat ventricular cells. Biochem. Biophys. Res. Commun. 375(4), 628–633 (2008). doi:10.1016/j.bbrc.2008.08.074
26. J. Pu, A. Yuan, P. Shan, E. Gao, X. Wang, Y. Wang, W.B. Lau, W. Koch, X.L. Ma, B. He, Cardiomyocyte-expressed farnesoid-X-receptor is a novel apoptosis mediator and contributes to myocardial ischaemia/reperfusion injury. Eur. Heart J. 34(24), 1834–1845 (2013). doi:10.1093/eurheartj/ehs011
27. A. Franczyk, K. Stolarz-Skrzypek, A. Wesolowska, D. Czarnecka, Vitamin D and vitamin D receptor activators in treatment of hypertension and cardiovascular disease. Cardiovasc. Hematol. Disord. Drug Targets 14(1), 34–44 (2014)
28. K. Yoneyama, O. Gjesdal, E.Y. Choi, C.O. Wu, W.G. Hundley, A.S. Gomes, C.Y. Liu, R.L. McClelland, D.A. Bluemke, J.A. Lima, Age, sex, and hypertension-related remodeling influences left ventricular torsion assessed by tagged cardiac magnetic resonance in asymptomatic individuals: the multi-ethnic study of atherosclerosis. Circulation 126(21), 2481–2490 (2012). doi:10.1161/circulationaha.112.093146
29. X. Xu, Y. Hua, S. Nair, R. Bucala, J. Ren, Macrophage migration inhibitory factor deletion exacerbates pressure overload-induced cardiac hypertrophy through mitigating autophagy. Hypertension 63(3), 490–499 (2014). doi:10.1161/hypertensionaha.113.02219
30. M.M. Mihaylova, R.J. Shaw, The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat. Cell Biol. 13(9), 1016–1023 (2011). doi:10.1038/ncb2329
31. N. Echeverry, G. Ziltener, D. Barbone, W. Weder, R.A. Stahel, V.C. Broaddus, E. Felley-Bosco, Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3 K/mTOR inhibitors. Cell Death Dis. 6, e1757 (2015). doi:10.1038/cddis.2015.124
32. A. Albu, S. Radian, S. Fica, C.G. Barbu, Biochemical hyperandrogenism is associated with metabolic syndrome independently of adiposity and insulin resistance in Romanian polycystic ovary syndrome patients. Endocrine 48(2), 696–704 (2015). doi:10.1007/s12020-014-0340-9
33. B. Dilbaz, E. Ozkaya, M. Cinar, E. Cakir, S. Dilbaz, Cardiovascular disease risk characteristics of the main polycystic ovary syndrome phenotypes. Endocrine 39(3), 272–277 (2011). doi:10.1007/s12020-011-9437-6
34. S. Wild, T. Pierpoint, H. Jacobs, P. McKeigue, Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study. Hum. Fertil. (Cam) 3(2), 101–105 (2000)
35. S. Wild, T. Pierpoint, P. McKeigue, H. Jacobs, Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin. Endocrinol. 52(5), 595–600 (2000)
36. F. Orio Jr, S. Palomba, L. Spinelli, T. Cascella, L. Tauchmanova, F. Zullo, G. Lombardi, A. Colao, The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J. Clin. Endocrinol. Metab. 89(8), 3696–3701 (2004). doi:10.1210/jc.2003-032049
37. G. Muscogiuri, V. Nuzzo, A. Gatti, A. Zuccoli, S. Savastano, C. Di Somma, R. Pivonello, F. Orio, A. Colao, Hypovitaminosis D: a novel risk factor for coronary heart disease in type 2 diabetes? Endocrine (2015). doi:10.1007/s12020-015-0609-7
38. S.E. Judd, S.N. Raiser, M. Kumari, V. Tangpricha, 1,25-dihydroxyvitamin D3 reduces systolic blood pressure in hypertensive adults: a pilot feasibility study. J. Steroid Biochem. Mol. Biol. 121(1–2), 445–447 (2010). doi:10.1016/j.jsbmb.2010.04.013
39. H.U. Simon, Autophagy in myocardial differentiation and cardiac development. Circ. Res. 110(4), 524–525 (2012). doi:10.1161/circresaha.112.265157
40. M. Xie, Y. Kong, W. Tan, H. May, P.K. Battiprolu, Z. Pedrozo, Z.V. Wang, C. Morales, X. Luo, G. Cho, N. Jiang, M.E. Jessen, J.J. Warner, S. Lavandero, T.G. Gillette, A.T. Turer, J.A. Hill, Histone deacetylase inhibition blunts ischemia/reperfusion injury by inducing cardiomyocyte autophagy. Circulation 129(10), 1139–1151 (2014). doi:10.1161/circulationaha.113.002416
41. J. Moscat, M.T. Diaz-Meco, p62 at the crossroads of autophagy, apoptosis, and cancer. Cell 137(6), 1001–1004 (2009). doi:10.1016/j.cell.2009.05.023
42. J.T. Fassett, X. Hu, X. Xu, Z. Lu, P. Zhang, Y. Chen, R.J. Bache, AMPK attenuates microtubule proliferation in cardiac hypertrophy. Am. J. Physiol. Heart Circ. Physiol. 304(5), H749–H758 (2013). doi:10.1152/ajpheart.00935.2011
43. Z. Xie, K. Lau, B. Eby, P. Lozano, C. He, B. Pennington, H. Li, S. Rathi, Y. Dong, R. Tian, D. Kem, M.H. Zou, Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice. Diabetes 60(6), 1770–1778 (2011). doi:10.2337/db10-0351
44. Q.D. Zhao, S. Viswanadhapalli, P. Williams, Q. Shi, C. Tan, X. Yi, B. Bhandari, H.E. Abboud, NADPH oxidase 4 induces cardiac fibrosis and hypertrophy through activating Akt/mTOR and NFkappaB signaling pathways. Circulation 131(7), 643–655 (2015). doi:10.1161/circulationaha.114.011079
45. T.S. Lisse, T. Liu, M. Irmler, J. Beckers, H. Chen, J.S. Adams, M. Hewison, Gene targeting by the vitamin D response element binding protein reveals a role for vitamin D in osteoblast mTOR signaling. FASEB J. 25(3), 937–947 (2011). doi:10.1096/fj.10-172577
46. G. Wu, Y. Liu, H. Huang, Y. Tang, W. Liu, Y. Mei, N. Wan, X. Liu, C. Huang, SH2B1 is critical for the regulation of cardiac remodelling in response to pressure overload. Cardiovasc. Res. 107(2), 203–215 (2015). doi:10.1093/cvr/cvv170